mab2 ip publications pipeline pipeline overview immuno oncology partnering opportunities & partners news & events press releases events f star in the news publications media about f star overview management team board scientific advisors investors scientific approach overview technology platform fcab mab2 ip publications pipeline pipeline overview immuno oncology partnering opportunities & partners news & events press releases events upcoming events past events f star in the news publications media welcome to f star f star develops novel bispecific antibodies directed at improving the treatment of serious diseases with a focus on immuno oncology . read more about f star modular antibody technology our robust discovery engine lets us easily mix and match antibody components to create unique bispecific antibody products . read more about our scientific approach pipeline f star develops genuine monoclonal bispecific antibodies that can bind two different targets at the same time for use as 2 in 1 drugs . view our pipeline company overview f star is a leader in the discovery and development of novel bispecific antibodies . we are a biopharmaceutical company focused on developing immuno oncology bispecific antibody therapeutics through the application of our highly efficient modular antibody technology platform . more about us statistics 100million raised in non dilutive capital and revenues 34billion estimated size of the immuno oncology market in 2024 immuno oncology immuno oncology leverages the body s natural immune response to fight cancer and is currently one the most exciting areas of research within the biopharmaceutical industry with several key drugs on the market and many in late stage clinical development . read more about our scientific approach fcab an fcab is derived from the constant fc region of an antibody the stem of an antibody . natural antibodies bind antigens via the variable fab regions the arms of an antibody . our platform introduces new antigen binding sites into the fc region . view all technologies meet the team f star s leadership team has decades of combined experience from holding senior level positions in both pharma and biotech and involving the development of dozens of biologics from target selection to clinical trials . find out more about our team latest news october 12 2016 news ddnews delving into drug delivery september 20 2016 f star to present encouraging preclinical data on lead bispecific programme fs118 at upcoming conferences september 07 2016 news bispecific antibody platforms spawn dealmaking boom view all news 2016 f star biotechnology limited . by emperor disclaimer cookie policy contact us sitemap get in touch